JP4740524B2 - 熱応答粘膜接着性医薬−担体組成物 - Google Patents

熱応答粘膜接着性医薬−担体組成物 Download PDF

Info

Publication number
JP4740524B2
JP4740524B2 JP2003059191A JP2003059191A JP4740524B2 JP 4740524 B2 JP4740524 B2 JP 4740524B2 JP 2003059191 A JP2003059191 A JP 2003059191A JP 2003059191 A JP2003059191 A JP 2003059191A JP 4740524 B2 JP4740524 B2 JP 4740524B2
Authority
JP
Japan
Prior art keywords
ala
carbopol
composition
weight
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003059191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003292459A5 (enExample
JP2003292459A (ja
Inventor
− ミン ツァイ ツイ
Original Assignee
ファーマ パワー バイオテク カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW91101510A external-priority patent/TWI299667B/zh
Priority claimed from CNB021032564A external-priority patent/CN1224424C/zh
Application filed by ファーマ パワー バイオテク カンパニー リミテッド filed Critical ファーマ パワー バイオテク カンパニー リミテッド
Publication of JP2003292459A publication Critical patent/JP2003292459A/ja
Publication of JP2003292459A5 publication Critical patent/JP2003292459A5/ja
Application granted granted Critical
Publication of JP4740524B2 publication Critical patent/JP4740524B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003059191A 2002-01-30 2003-01-29 熱応答粘膜接着性医薬−担体組成物 Expired - Lifetime JP4740524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW091101510 2002-01-30
TW91101510A TWI299667B (en) 2002-01-30 2002-01-30 A mucoadhesive thermoresponsive medicament-carrier composition
CNB021032564A CN1224424C (zh) 2002-02-01 2002-02-01 粘膜吸附性的热凝性医药载体组合物

Publications (3)

Publication Number Publication Date
JP2003292459A JP2003292459A (ja) 2003-10-15
JP2003292459A5 JP2003292459A5 (enExample) 2005-10-27
JP4740524B2 true JP4740524B2 (ja) 2011-08-03

Family

ID=30116452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003059191A Expired - Lifetime JP4740524B2 (ja) 2002-01-30 2003-01-29 熱応答粘膜接着性医薬−担体組成物

Country Status (2)

Country Link
US (2) US20040009212A1 (enExample)
JP (1) JP4740524B2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
WO2006081473A2 (en) * 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
US7851189B2 (en) * 2005-03-07 2010-12-14 Boston Scientific Scimed, Inc. Microencapsulated compositions for endoluminal tissue engineering
WO2006133349A2 (en) * 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
EP2034963B1 (en) * 2006-05-18 2022-08-10 biolitec Unternehmensbeteiligungs II AG Gel-formulations of hydrophobic photosensitizers for mucosal applications
US20080279921A1 (en) * 2007-05-07 2008-11-13 Ceramoptec Industries, Inc. Gel-formulations of hydrophobic photosensitizers for mucosal applications
WO2009073457A1 (en) * 2007-11-30 2009-06-11 Bausch & Lomb Incorporated Methods and compositions for the rescue of a filtering bleb
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
KR100935711B1 (ko) 2008-09-12 2010-01-07 김희구 생약 패드
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
US20100256125A1 (en) * 2009-04-06 2010-10-07 Zila Pharmaceuticals, Inc. Use of improved toluidine blue in photodynamic therapy
WO2010142457A1 (en) * 2009-06-11 2010-12-16 Photocure Asa Semi-solid compositions and pharmaceutical products
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
KR20150043548A (ko) 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
DE212011100034U1 (de) 2010-01-20 2012-07-04 Theracoat Ltd. Material zur Behandlung von inneren Hohlräumen
US10471150B2 (en) * 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
JP6076962B2 (ja) 2011-04-01 2017-02-08 フロリダ大学 リサーチファウンデーション インコーポレイティッド 治療薬を局所送達するための感熱性を有する粘膜付着性または皮膚粘着性の浸透促進剤
WO2013011504A1 (en) * 2011-07-20 2013-01-24 Theracoat Ltd. Materials and method for treating internal body cavities
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
DK2836200T3 (da) * 2012-04-08 2020-09-21 Urogen Pharma Ltd Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US9801854B1 (en) * 2014-01-17 2017-10-31 Urogen Pharma Ltd. Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer
AR100864A1 (es) * 2014-06-09 2016-11-09 Klox Tech Inc Composiciones biofotónicas termoendurecibles y sus usos
AU2015301945B2 (en) 2014-08-11 2020-05-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Delivery of bioactive, nanoencapsulated antioxidants
DE102016001176A1 (de) * 2016-02-03 2017-08-03 Audi Ag Kraftfahrzeug
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
EP3790856A4 (en) * 2018-05-08 2022-03-02 University of Connecticut LONG-ACTING LOCAL ANESTHETIC FORMULATION
EP3833401A4 (en) * 2018-08-06 2022-04-27 Oregon Health & Science University NERVE-SPECIFIC FLUOROPHORUS FORMULATIONS FOR DIRECT AND SYSTEMIC DELIVERY
EP3854422B1 (en) * 2018-09-20 2025-01-22 FUJIFILM Corporation Biomaterial
CN112043827B (zh) * 2019-05-20 2023-10-20 复旦大学 温敏性药物组合物、透皮制剂及其制备方法和应用
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
KR20230118632A (ko) 2020-12-11 2023-08-11 우로젠 파마 엘티디. 암을 치료하기 위한 물질 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
MX9504023A (es) * 1994-09-20 1997-05-31 Johnson & Johnson Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
DE19744811C2 (de) * 1997-10-02 1999-11-18 Medac Klinische Spezialpraep Verwendung von delta-Aminolävulinsäure zur Herstellung eines topischen Arzneimittels zur integralen Diagnose und/oder Therapie von Tumoren in Hohlorganen
PL349773A1 (en) * 1999-01-08 2002-09-09 3M Innovative Properties Co Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6333194B1 (en) * 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof

Also Published As

Publication number Publication date
US20070231352A1 (en) 2007-10-04
US20040009212A1 (en) 2004-01-15
JP2003292459A (ja) 2003-10-15

Similar Documents

Publication Publication Date Title
US20070231352A1 (en) Mucoadhesive thermoresponsive medicament-carrier composition
US20250235538A1 (en) Methods for photodynamic therapy
Chen et al. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5‐aminolevulinic acid‐mediated photodynamic therapy
ES2358760T3 (es) Compuesto de fenotiazinio para curación de las heridas.
EP2440199B1 (en) Semi-solid compositions and pharmaceutical products
JP2025176048A5 (enExample)
CN105770894B (zh) 盐酸氨酮戊酸温度敏感型原位凝胶制剂及其制备方法
CZ2003553A3 (cs) Farmaceutický prostředek
CN1585646A (zh) 用于治疗皮下软组织疼痛的锶化合物
WO2010072419A2 (en) Enema preparations and their use
US20240108603A1 (en) Material and method for treating cancer
EP1332764B1 (en) A mucoadhesive thermoresponsive medicament-carrier composition
CN101455654A (zh) 精氨酸布洛芬凝胶剂及其制备方法
TWI299667B (en) A mucoadhesive thermoresponsive medicament-carrier composition
US9492682B2 (en) Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
CN113908271A (zh) 一种凝胶制剂的制备方法
CN100484520C (zh) 一种5-氨基酮戊酸盐外用制剂及其制备方法
CN119326740A (zh) 一种治疗生物节律失调的鼻脑递释制剂
CN1700914A (zh) 口腔等粘膜中的炎性疾病的预防或治疗剂
Upreti et al. EXPLORING THE POTENTIAL OF BIOADHESIVE DRUG DELIVERY SYSTEMS: A COMPREHENSIVE REVIEW ON BIOADHESIVE DOSAGE FORMS
TW202317195A (zh) 一種傳遞生物活性化合物之可抗菌具溫感性的凝膠載劑組合物
WO2025077886A1 (zh) 治疗和/或预防日光性角化病的化合物及方法
WO2025077888A1 (zh) 一种适合外用的化合物及药物组合物
CN118903014A (zh) 一种基于传递体的抗甲真菌/光敏药物透甲递送载体及其制备方法和应用
HK40093030A (en) Drug containing glycopyrronium salicylate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100921

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101019

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110502

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4740524

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140513

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term